Q3 Earnings Estimate for NRXP Issued By HC Wainwright

Key Points

• Research analysts from HC Wainwright have projected NRx Pharmaceuticals will report a Q3 2025 earnings per share of ($0.08), maintaining a "Buy" rating with a price target of $40.00 for the stock.
• Several brokerages have reaffirmed their positive outlook on NRx Pharmaceuticals, with a consensus rating of "Buy" and an average target price of $34.50.
• NRx Pharmaceuticals' stock price opened at $3.15 after experiencing a significant trading increase of 10.9% recently.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - HC Wainwright issued their Q3 2025 earnings per share estimates for shares of NRx Pharmaceuticals in a research report issued on Monday, September 8th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals' current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals' Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.11 EPS, FY2027 earnings at $2.53 EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at $5.49 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings data on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.67).

Other equities analysts also recently issued research reports about the company. Wall Street Zen upgraded NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. D. Boral Capital reissued a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday. BTIG Research reissued a "buy" rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Finally, Zacks Research raised shares of NRx Pharmaceuticals to a "hold" rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, NRx Pharmaceuticals currently has an average rating of "Buy" and an average target price of $34.50.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock traded down $0.08 during mid-day trading on Wednesday, hitting $2.80. The company's stock had a trading volume of 482,404 shares, compared to its average volume of 508,943. The company's fifty day simple moving average is $2.79 and its 200-day simple moving average is $2.56. The company has a market cap of $55.47 million, a PE ratio of -1.25 and a beta of 1.63. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $56,000. Millennium Management LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $61,000. Geode Capital Management LLC raised its holdings in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock valued at $562,000 after acquiring an additional 37,598 shares during the period. Finally, Anson Funds Management LP raised its holdings in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock valued at $2,417,000 after acquiring an additional 993,401 shares during the period. Institutional investors own 4.27% of the company's stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.